Medtronic and Philips, today announced a new partnership to develop and commercialize the LungGPS Patient Management Platform. The comprehensive patient and data management platform is designed to make it easier for clinicians to identify and manage potentially cancerous lung nodules.
Lung cancer is the deadliest form of cancer, and while early detection is key, there are few symptoms in the earlier stages. When found early, lung nodules can be continuously monitored for growth, which is a sign that the nodule could become cancerous. However, the current management of incidental lung nodule tracking is a very manual process that includes little active management. This lack of infrastructure, coordination and capacity can lead to delays in diagnosis and treatment.
How It Works
The LungGPS Patient Management Platform changes the way healthcare providers can tackle this deadly disease by helping identify at-risk patients and guide them into an appropriate clinical workflow. It allows for quick evaluation of those who may be at risk of lung cancer and effective and efficient management of those who require long-term surveillance.
“Early identification and prompt, appropriate management of pulmonary nodule patients has been proven to improve clinical outcomes. Developing technological solutions to enable our customers to do this quickly, efficiently and consistently continues to be our focus and we’re excited about the expanded possibilities through our new collaboration with Medtronic,” said Brent Berthy, head of Oncology Solutions at Philips. “The combination of our collective capabilities in imaging, informatics and image-guided intervention has the ability to make a meaningful, positive impact on patient care, clinical outcomes and survivorship.”
Featured image credit: GreenFlames09 via creative commons
